600211 西藏药业
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)22.70725.20013.1108.02616.680
总资产报酬率 ROA (%)17.10618.4399.3606.19414.640
投入资产回报率 ROIC (%)19.73121.71111.0287.23016.625

边际利润分析
销售毛利率 (%)94.92895.05294.25889.56285.801
营业利润率 (%)40.65628.68518.18912.00834.383
息税前利润/营业总收入 (%)38.65927.58118.30712.23233.266
净利润/营业总收入 (%)36.55125.85114.6919.96130.636

收益指标分析
经营活动净收益/利润总额(%)86.909119.799160.019222.55889.722
价值变动净收益/利润总额(%)0.967-18.937-1.54157.4740.202
营业外收支净额/利润总额(%)-0.184-0.100-0.272-0.765-0.383

偿债能力分析
流动比率 (X)3.5772.8732.6431.9664.056
速动比率 (X)3.4362.7792.5451.8433.844
资产负债率 (%)21.56526.45826.07230.4430.121
带息债务/全部投入资本 (%)12.16412.56513.21015.9850.128
股东权益/带息债务 (%)716.017689.815647.811516.18077,614.078
股东权益/负债合计 (%)360.363275.561281.766227.218723.810
利息保障倍数 (X)-20.106-25.643108.98638.756-33.728

营运能力分析
应收账款周转天数 (天)69.54263.03864.69167.69283.922
存货周转天数 (天)304.547245.342291.134167.867134.294